Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Weekly Adalimumab, an Effective Alternative for Refractory Uveitis in Children.

Literature DB >> 33790207

Weekly Adalimumab, an Effective Alternative for Refractory Uveitis in Children.

Jordan E Roberts¹, Peter A Nigrovic, Mindy S Lo¹, Margaret H Chang¹.

Abstract

Entities: Chemical

Mesh：

Substances：
Adalimumab

Year: 2022 PMID： 33790207 PMCID： PMC8443693 DOI： 10.1097/RHU.0000000000001707

Source DB: PubMed Journal: J Clin Rheumatol ISSN： 1076-1608 Impact factor: 3.517

× No keyword cloud information.

13 in total

1. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease.

Authors: Grace K H Choi; Stephanie D E Collins; Daniel P Greer; Lisa Warren; Grace Dowson; Tanya Clark; P John Hamlin; Alexander C Ford
Journal: J Crohns Colitis Date: 2013-10-12 Impact factor: 9.071

2. Adalimumab in Patients with Active Noninfectious Uveitis.

Authors: Glenn J Jaffe; Andrew D Dick; Antoine P Brézin; Quan Dong Nguyen; Jennifer E Thorne; Philippe Kestelyn; Talin Barisani-Asenbauer; Pablo Franco; Arnd Heiligenhaus; David Scales; David S Chu; Anne Camez; Nisha V Kwatra; Alexandra P Song; Martina Kron; Samir Tari; Eric B Suhler
Journal: N Engl J Med Date: 2016-09-08 Impact factor: 91.245

3. Success of Weekly Adalimumab in Refractory Ocular Inflammatory Disease.

Authors: Jennifer Lee; Anjum F Koreishi; Katelyn B Zumpf; Caroline L Minkus; Debra A Goldstein
Journal: Ophthalmology Date: 2020-04-17 Impact factor: 12.079

4. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain.

Authors: Cristina Trigo-Vicente; Vicente Gimeno-Ballester; Alejandro López-Del Val
Journal: Eur J Hosp Pharm Date: 2019-05-07

5. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.

Authors: Quan Dong Nguyen; Pauline T Merrill; Glenn J Jaffe; Andrew D Dick; Shree Kumar Kurup; John Sheppard; Ariel Schlaen; Carlos Pavesio; Luca Cimino; Joachim Van Calster; Anne A Camez; Nisha V Kwatra; Alexandra P Song; Martina Kron; Samir Tari; Antoine P Brézin
Journal: Lancet Date: 2016-08-16 Impact factor: 79.321

6. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis.

Authors: Colleen K Correll; Danielle R Bullock; Rachel M Cafferty; Richard K Vehe
Journal: Clin Rheumatol Date: 2017-11-04 Impact factor: 2.980

Review 7. Does switching anti-TNFα biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach.

Authors: Gabriele Simonini; Druce Katie; Rolando Cimaz; Gary J Macfarlane; Gareth T Jones
Journal: Semin Arthritis Rheum Date: 2014-03-06 Impact factor: 5.532

8. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.

Authors: Athimalaipet V Ramanan; Andrew D Dick; Ashley P Jones; Andrew McKay; Paula R Williamson; Sandrine Compeyrot-Lacassagne; Ben Hardwick; Helen Hickey; Dyfrig Hughes; Patricia Woo; Diana Benton; Clive Edelsten; Michael W Beresford
Journal: N Engl J Med Date: 2017-04-27 Impact factor: 91.245